文献速递慢阻肺呼吸道感染

慢阻肺加速肺功能下降与黏液-微生物组演变

Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

该前瞻性纵向研究评估伦敦COPD队列中FEV1下降最快者(n=30,年降156 ml)与无下降者(n=28,年升49 ml)的痰液微生物组和黏液特性。加速下降组黏液生化与生物物理特性显著改变,并出现黏液-微生物组关联,随GOLD分期进展呈现不同黏液-微生物特征。

要点

  • 加速FEV1下降的COPD患者黏液生化与生物物理特性显著改变。
  • 加速下降组黏液-微生物组关联表现为MUC5AC和MUC5B浓度升高及Achromobacter和Klebsiella出现。
  • 随COPD进展,黏液-微生物组从低黏蛋白、黏性向弹性转变演变为高黏度、高黏蛋白和DNA及病原体出现。

核心结论

  • COPD中黏液-微生物组关联随时间演变,与加速肺功能下降、症状进展和急性加重相关。

研究设计与样本

  • 前瞻性纵向评估伦敦COPD队列中FEV1下降最快者(n=30,年降156 ml)与无FEV1下降者(n=28,年升49 ml)。
  • 配对痰液共116份标本行鸟枪法宏基因组学及黏液生化和生物物理特性评估。

主要发现

  • 加速下降组黏液生化和生物物理特性显著改变。
  • 无监督主成分分析显示清晰分离,黏液生化与加速下降相关,生物物理特性贡献个体间变异。
  • 加速下降黏液-微生物组关联表现为MUC5AC和MUC5B浓度升高及Achromobacter和Klebsiella存在。
  • GOLD A和B期以低黏蛋白浓度、黏性向弹性转变及Veillonella、Gemella、Rothia和Prevotella为特征。
  • GOLD E期转变为黏液黏度、黏蛋白和DNA浓度升高,伴Haemophilus、Moraxella和Pseudomonas等病原微生物出现。

临床怎么用

  • 对COPD患者可关注黏液特性与微生物组变化,作为加速肺功能下降的早期干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Progressive lung function loss is recognized in chronic obstructive pulmonary disease (COPD); however, no study concurrently evaluates how accelerated lung function decline relates to mucus properties and the microbiome in COPD. Objectives: Longitudinal assessment of mucus and microbiome changes accompanying accelerated lung function decline in patients COPD. Methods: This was a prospective, longitudinal assessment of the London COPD cohort exhibiting the greatest FEV1 decline (n = 30; accelerated decline; 156 ml/yr FEV1 loss) and with no FEV1 decline (n = 28; nondecline; 49 ml/yr FEV1 gain) over time. Lung microbiomes from paired sputum (total 116 specimens) were assessed by shotgun metagenomics and corresponding mucus profiles evaluated for biochemical and biophysical properties. Measurements and Main Results: Biochemical and biophysical mucus properties are significantly altered in the accelerated decline group. Unsupervised principal component analysis showed clear separation, with mucus biochemistry associated with accelerated decline, whereas biophysical mucus characteristics contributed to interindividual variability. When mucus and microbes are considered together, an accelerated decline mucus-microbiome association emerges, characterized by increased mucin (MUC5AC [mucin 5AC] and MUC5B [mucin 5B]) concentration and the presence of Achromobacter and Klebsiella. As COPD progresses, mucus-microbiome shifts occur, initially characterized by low mucin concentration and transition from viscous to elastic dominance accompanied by the commensals Veillonella, Gemella, Rothia, and Prevotella (Global Initiative for Chronic Obstructive Lung Disease [GOLD] A and B) before transition to increased mucus viscosity, mucins, and DNA concentration together with the emergence of pathogenic microorganisms including Haemophilus, Moraxella, and Pseudomonas (GOLD E). Conclusions: Mucus-microbiome associations evolve over time with accelerated lung function decline, symptom progression, and exacerbations affording fresh therapeutic opportunities for early intervention.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Meldrum OW, Donaldson GC, Narayana JK, et al. Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2024. PMID: 38315959. doi:10.1164/rccm.202306-1060OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。